Report on Point Prevalence Survey of Antibacterial Prescribing at Ysbyty Gwynedd Hospital November 2008

Similar documents
Report on the Point Prevalence Survey of Antimicrobial Prescribing in Secondary Care in Wales November/December 2009

Antibacterial Usage in Secondary Care in Wales

Monthly Webinar. Tuesday 12th December 2017, 16:00 Brewing Up a Little Storm. Event number: Audio dial-in (phone):

POINT PREVALENCE SURVEY A tool for antibiotic stewardship in hospitals. Koen Magerman Working group Hospital Medicine

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Surveillance of antimicrobials - establishing a national point prevalence system. Maggie Heginbothom Public Health Wales

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.

Surveillance of Antimicrobial Use and Resistance in Northern Ireland, Annual Report, 2017

Swedish strategies and methods to combat antibiotic resistance

What can we learn from point prevalence surveys? Mark Gilchrist Consultant Pharmacist Infectious Diseases

Tanzania Journal of Health Research Volume 12, Number 3, July 2010

EUCAST recommended strains for internal quality control

Antibacterial Resistance In Wales

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

INFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT

A Retrospective Study on Antibiotic Use in Different Clinical Departments of a Teaching Hospital in Zawiya, Libya

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

POINT PREVALENCE SURVEY OF HEALTHCARE ASSOCIATED INFECTIONS, MEDICAL DEVICE USAGE AND ANTIMICROBIAL USAGE

- the details, where possible, of the antibiotic products these companies supply or have supplied.

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Intro Who should read this document 2 Key practice points 2 Background 2

Women s Antimicrobial Guidelines Summary

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

Global Point Prevalence Survey (PPS) Year 2017 (GLOBAL-PPS)

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

How is Ireland performing on antibiotic prescribing?

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia

Antibacterial Resistance In Wales

GENERAL NOTES: 2016 site of infection type of organism location of the patient

INFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT

your hospitals, your health, our priority PARC (Policy Approval and Ratification Committee) STANDARD OPERATING PROCEDURE:

Antimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

National Point Prevalence Survey of Healthcare Associated Infection, Device Usage and Antimicrobial Prescribing Wales. HCAI and AMR Programme

Inappropriate Antibiotic Utilization: Outpatient Prescription Review of a Regional Secondary Hospital in Kedah, Malaysia

Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance

Antibacterial Resistance in Wales

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.

Volume 1; Number 7 November 2007

Drug Use Evaluation of Antimicrobials in Healthcare Resource Limited Settings of India

* gender factor (male=1, female=0.85)

ake National Point Prevalence Survey of Healthcare Associated Infections, Device usage and Antimicrobial use in Long-Term Care Facilities 2017 HALT-3

Hospital ID: 831. Bourguiba Hospital. Tertiary hospital

Public policy to reduce antibiotic resistance Prof. Niels Frimodt-Moller

National Antimicrobial Prescribing Survey

European Committee on Antimicrobial Susceptibility Testing

REPORT ON POINT PREVALENCE SURVEY OF ANTIMICROBIAL PRESCRIPTION IN EUROPEAN NURSING HOMES, November 2009

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

DRAFT DRAFT. Paediatric Antibiotic Prescribing Guideline. May

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Antimicrobial susceptibility

Measurement of Antimicrobial Drug Use. Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist

Antibacterial Resistance In Wales

Volume 2; Number 16 October 2008

The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England

CONSUMPTION OF ANTIBIOTICS IN PUBLIC ACUTE HOSPITALS IN IRELAND DATA TO END OF 2012

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.

Volume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.

2015 Antibiotic Susceptibility Report

Rational management of community acquired infections

Department of Pharmacology, Father Muller Medical College Hospital, Mangalore ,INDIA.

GUIDELINES FOR IV TO ORAL SWITCH FOR ANTIBITOICS

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Received: Accepted: Access this article online Website: Quick Response Code:

Antibiotic Stewardship at MetroWest Medical Center. Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

AMR Industry Alliance Antibiotic Discharge Targets

NEONATAL Point Prevalence Survey. Ward Form

Antibiotic Usage Guidelines in Hospital

European Committee on Antimicrobial Susceptibility Testing

Quality indicators and outcomes in the devolved nations Scotland

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

Antimicrobial Stewardship in Scotland

Antimicrobial Susceptibility Patterns

2016 Antibiotic Susceptibility Report

RCH antibiotic susceptibility data

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)

Measure Information Form

Antimicrobial Susceptibility Testing: Advanced Course

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals

Antimicrobial Stewardship. Where are we now and where do we need to go?

Clinical Practice Standard

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

Aminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.

ANTIBIOTIC FORMULARY AND PRESCRIBING ADVICE FOR PAEDIATRIC PATIENTS OTHER THAN NEONATES

HSE - Health Protection Surveillance Centre Surveillance of Antimicrobial Consumption in Ireland

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS

Antibiotics utilization ratio in a Neonatal Intensive Care Unit

Measuring Antibiotic Use in NHSN

Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

ANTHRAX. INHALATION, INTESTINAL and CUTANEOUS ANTHRAX

Update on current SAPG projects

Community-Acquired Pneumonia: Severity scoring and compliance to BTS guidelines. Julie Harris Antibiotic Pharmacist Hywel Dda Healthboard

Transcription:

Report on Point Prevalence Survey of Antibacterial Prescribing at Ysbyty Gwynedd Hospital November 2008 Authors: Maggie Heginbothom Robin Howe Version: 1 Antibacterial PPS Ysbyty Gwynedd Date: 29/05/2009 Page: 1 of 19 Status: Draft Welsh Antibacterial Resistance Programme: Surveillance Unit

Introduction This report provides a simple analysis of data collected as part of the Wales Point Prevalence Survey (PPS) of antibacterial usage in secondary care; the PPS was supported and carried out by pharmacists in nineteen hospitals across the principality during November/December 2008 to mark the first European antibacterial awareness day (18 th November 2008). Summary of Antimicrobial use at Ysbyty Gwynedd 385 patients were surveyed 34.5% of patients surveyed were receiving an antibacterial o 16.1% for a community-acquired infection o 10.1% for a hospital-acquired infection o 3.9% for surgical prophylaxis o 1.0% for medical prophylaxis o 3.5% for mixed or unknown indications 28 different antibacterials were used o The commonest agents were metronidazole, cefotaxime, amoxicillin, ciprofloxacin & cefalexin o 36.8% of patients receiving an antibacterial received more than one agent Community-acquired infection (CAI) was the indication for 49.6% of patients receiving an antibacterial o 23 different antibacterials were used o Respiratory infections (CA-RTI) were the commonest indication for antibacterials 40.9% of patients prescribed for a CAI 45% of antibacterials prescribed for CAI o Amoxicillin monotherapy was the most commonly prescribed regimen for CA-RTI Hospital-acquired infection (HAI) was the indication for 33.8% of patients receiving an antibacterial o 23 different antibacterials were used o The commonest sites of infection was skin soft tissue bone and joint 33% Surgical prophylaxis was the indication for 12% of patients receiving an antibacterial o 36.8% of patients received prophylaxis for more than 1 day Medical prophylaxis was the indication for 3.0% of patients receiving an antibacterial 2

Hospital: Ysbyty Gwynedd The PPS at Ysbyty Gwynedd was carried out on the 18 th of November 2008 Patient Information 385 patients were surveyed 194 of the patients were general medicine patients (50.4%) 182 of the patients were surgical patients (47.3%) 9 of the patients were intensive care patients (2.3%) Of the 385 patients surveyed 133 were prescribed systemic antimicrobial/s (34.5%). o 128 were prescribed systemic antibacterials o 1 was prescribed antibacterials including anti-tb drugs o 3 were prescribed antibacterials and a systemic antifungal o 1 was prescribed antibacterials and a systemic antiviral For the purposes of the report only systemic antibacterial data is included in the analysis. Age group & gender of patients receiving antimicrobials inlcuded in the Ysbyty Gwynedd PPS 35 30 25 20 15 10 5 0 15-29 30-44 45-59 60-74 75+ F 2 6 8 14 26 M 2 7 12 24 32 Figure 1: Age group & gender of patients prescribed antibacterials. The age and gender of the 133 patients prescribed antimicrobials is shown in Figure 1. Over 70% of the patients that were prescribed an antimicrobial/s were 60+ in age (72.2%); in this PPS study group 57.9% of the patients were male and 42.1% were female. 3

Clinical indication The PPS included four main indications for antibacterial usage: A Community acquired infection B Hospital acquired infection C Surgical prophylaxis D Medical prophylaxis Of the 385 patients surveyed antibacterial agents were prescribed for the following clinical indications (See Figure 2): 62 patients were prescribed an antibacterial/s for a community acquired infection (16.1%) 39 patients were prescribed an antibacterial/s for a hospital acquired infection (10.1%) 15 patients were prescribed an antibacterial/s for surgical prophylaxis (3.9%) 4 patients were prescribed an antibacterial/s for medical prophylaxis (1.0%) 5 patients were prescribed an antibacterial/s for a community acquired infection and a hospital acquired infection (1.3%) 1 patient was prescribed an antibacterial/s for a community acquired infection and for surgical prophylaxis (0.3%) 1 patient was prescribed an antibacterial/s for a community acquired infection and for an unknown indication (0.3%) 1 patient was prescribed an antibacterial/s for a hospital acquired infection and for medical prophylaxis (0.3%) 1 patient was prescribed an antibacterial/s for a hospital acquired infection and for an unknown indication (0.3%) 4 patients were prescribed antibacterial/s unknown indications (1.0%) 252 patients were not prescribed an antibacterial/s (65.5% - NoABx) NoABx, 252, 66% U, 4, 1% A, 62, 17% B&U, 1, 0% B, 39, 10% C, 15, 4% D, 4, 1% A&B, 5, 1% A&C, 1, 0% A&U, 1, 0% B&D, 1, 0% A B C D A&B A&C A&U B&D B&U U NoABx Figure 2: Clinical indication for antibacterial prescribing in patients (n = 385) 4

Ward Information Patients from 17 wards/units were included in the Ysbyty Gwynedd PPS. The ward specialty, the number of patients surveyed on the ward, and the number of patients prescribed antimicrobials at or before 8:00 am on the day of the PPS are shown in Table 1. Table 1: Ward information Ward Specialty Patients on ward No. prescribed antibacterials Alaw General Medicine 16 7 43.8 Glaslyn General Medicine 30 11 36.7 Glyder/CCU General Medicine 24 5 20.8 Gogarth General Medicine 29 6 20.7 Hebog General Medicine 27 9 33.3 Moelwyn General Medicine 30 17 56.7 Prysor General Medicine 15 6 40.0 Tryfan General Medicine 23 8 34.8 Aran Surgery 26 6 23.1 Beuno Surgery 20 2 10.0 Conwy Surgery 26 5 19.2 Dulas Surgery 29 18 62.1 Enlli Surgery 18 7 38.9 Ffrancon Surgery 15 3 20.0 Ogwen Surgery 29 13 44.8 Tegid Surgery 19 3 15.8 ITU ITU/HDU 9 7 77.8 % prescribed antibacterials Speciality Information 55 general medicine patients were prescribed antibacterial/s (29.9%) 71 surgical patients were prescribed antibacterial/s (38.8%) 7 intensive care patients were prescribed antibacterial/s (38.9%) Indication for antibacterial The indications recorded for antibacterial usage in the 133 patients included in the PPS are shown in Figure 3. 99 antibacterials were prescribed for community acquired infections (50%) 67 antibacterials were prescribed for hospital acquired infections (33.8%) 19 antibacterials were prescribed for surgical prophylaxis (9.6%) 7 antibacterials were prescribed for medical prophylaxis (3.5%) For 6 antibacterials the indication was unknown (3%) 5

U, 6, 3% D, 7, 4% C, 19, 10% B, 67, 34% A, 99, 49% A B C D U Figure 3: Antibacterial usage by indication The indication for each of the antibacterial prescribed for the patients on each ward is shown in Figure 4. The ward with the highest number of antibacterials prescribed on the day of the PPS was Dulas (30 prescribed). The indications for the antibacterials prescribed were: 15 for community acquired infections, 11 for hospital acquired infections, 1 for surgical prophylaxis & 2 for unknown indications. Indications for antibacterial usage by ward/unit Ysbyty Gwynedd PPS - November 2008 Tryfan Tegid Prysor Ogwen Moelwyn ITU Hebog Gogarth Glyder/CCU Glaslyn Ffrancon Enlli Dulas Conwy Beuno Aran Alaw A B C D U 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 Figure 4: Indication for antibacterial usage by ward 6

The proportion of instances where the reason for an antibacterial prescription was recorded in the patient notes is shown in Table 2. Table 2: Reason for prescription recorded in the notes Indication No Yes Unknown Total % Yes A 35 63 1 99 63.6 B 17 50 67 74.6 C 7 12 19 63.2 D 3 4 7 57.1 Unknown 6 0 6 0.0 All indications 68 129 1 198 65.2% Overall, the reason for a prescription was recorded in 65.2% of cases. 7

Antibacterial Information Twenty eight different antibacterials were prescribed as treatment/prophylaxis in this patient group (see Table 3); comprising 194 issues to 133 patients: Table 3: Antibacterials included in PPS group Antibacterial ATC code Number of Issues Metronidazole J01XD01 32 Cefotaxime J01DD01 19 Amoxicillin J01CA04 18 Ciprofloxacin J01MA02 15 Cefalexin J01DB01 14 Cefuroxime J01DC02 12 Flucloxacillin J01CF05 11 Clarithromycin J01FA09 10 Vancomycin J01XA01 9 Co-amoxiclav J01CR02 8 Erythromycin J01FA01 5 Gentamicin J01GB03 5 Trimethoprim J01EA01 5 Ceftazidime J01DD02 4 Penicillin V J01CE02 4 Piperacillin/Tazobactam J01CR05 4 Benzylpenicillin J01CE01 3 Clindamycin J01FF01 2 Colistin J01XB01 2 Doxycycline J01AA02 2 Fusidic Acid J01XC01 2 Meropenem J01DH02 2 Amikacin J01GB06 1 Ethambutol J04AK02 1 Imipenem J01DH51 1 Nitrofurantoin J01XE01 1 Norfloxacin J01MA06 1 Rifampicin J04AB02 1 All-antibacterials J01 194 There were 35 different combinations of antibacterial prescribed in this group; the most common were: Cefotaxime plus clarithromycin (prescribed for 4 patients) Cefotaxime plus metronidazole (prescribed for 4 patients) Cefuroxime plus metronidazole (prescribed for 4 patients) 8

Figure 5 shows the proportion of antibacterials prescribed by indication (A-D); monotherapy was prescribed in 60.6% of patients with community acquired infections (A), compared to 55.8% with hospital acquired infections (B) and 81.3% for surgical prophylaxis (C). The numbers of antibacterials prescribed for medical prophylaxis were too small to make any meaningful conclusions for this type of prescribing. Proportion 100 90 80 70 60 50 40 30 20 10 0 A B C D U Monotherapy 60.6 55.8 81.3 75.0 100 2 Antibacterials 31.8 32.6 12.5 25.0 0.0 3 Antibacterials 7.6 11.6 6.3 0.0 0.0 Proportion of antibacterials/indication Figure 5: Prescriptions for antibacterial usage by indication Diagnosis groups The PPS included ten diagnosis groups based on anatomical site: Central nervous system (CNS) Eye Ear, nose, throat, mouth or larynx (ENT) Respiratory tract (RESP) Cardiovascular system (CVS) Gastrointestinal tract including liver and biliary tree (GI) Skin, soft tissue, bone and joint (SSTBJ) Urinary tract (UTI) Genitourinary tract (GUOB) No clear anatomical site (Not Defined) 9

Community Acquired Infections (A) The antibacterials prescribed for community acquired infections (A) and the proportion of issues administered parenterally is show in Table 4. 66 patients of the 385 patients surveyed were prescribed antimicrobial/s for community acquired infections (17.1%) Of the 133 patients in the survey that were prescribed antibacterials, 66 (49.6%) were indicated for community acquired infections (A). 23 different antibacterials were prescribed within this group. Table 4: Antibacterials prescribed for community acquired infections (A) Antibacterial ATC code Number of Issues % IV administration Cefotaxime J01DD01 14 100 Amoxicillin J01CA04 13 0 Metronidazole J01XD01 11 45.5 Clarithromycin J01FA09 9 22.2 Cefalexin J01DB01 8 0 Ciprofloxacin J01MA02 6 16.7 Flucloxacillin J01CF05 5 25 Co-amoxiclav J01CR02 4 33.3 Vancomycin J01XA01 4 75 Erythromycin J01FA01 3 0 Gentamicin J01GB03 3 66.7** Piperacillin/Tazobactam J01CR05 3 100 Benzylpenicillin J01CE01 2 100 Penicillin V J01CE02 2 0 Trimethoprim J01EA01 2 0 Amikacin J01GB06 1 0 Ceftazidime J01DD02 1 100 Cefuroxime J01DC02 1 100 Clindamycin J01FF01 1 0 Colisitin J01XB01 1 0** Doxycycline J01AA02 1 0 Ethambutol J04AK02 1 0 Nitrofurantoin J01XE01 1 0 Rifampicin J04Ab02 1 0 All-antibacterials J01 98 35.7% ** One prescription for gentamicin and for colistin was for inhaled use. The antibacterials most commonly prescribed for community acquired infections were: Cefotaxime (14.3% of all issues for indication A) Amoxicillin (13.3% of all issues for indication A Metronidazole (11.2% of all issues for indication A) Clarithromycin (9.2% of all issues for indication A) 10

Figure 6 shows that 45% of the antibacterials prescribed for community acquired infections were for respiratory tract infections. UTI, 13, 13% CNS, 4, 4% CVS, 2, 2% ENT, 1, 1% GI, 9, 9% MIX, 1, 1% SSTBJ, 18, 18% RESP, 43, 45% Not Defined, 7, 7% CNS CVS ENT GI MIX Not Defined RESP SSTBJ UTI Figure 6: Antibacterial prescribed for indication A by diagnosis group The number of antibacterials prescribed and the diagnosis groups excluding respiratory (RESP) for community acquired infections is shown in Table 5. Table 5: Antibacterials prescribed by diagnosis group Indication A Antibacterial Not Defined SSTBJ UTI Name CNS CVS ENT GI MIX Amoxicillin 1 Benzylpenicillin 1 1 Cefalexin 1 1 1 4 Cefotaxime 2 1 1 4 Cefuroxime 1 Ciprofloxacin 1 3 Clarithromycin 1 1 Clindamycin 1 Co-amoxiclav 1 1 Erythromycin 1 Flucloxacillin 5 Gentamicin 1 Metronidazole 4 2 3 Nitrofurantoin 1 Penicillin V 2 Pip/Tazobactam 1 1 Trimethoprim 1 1 Vancomycin 1 1 2 All-antibacterials 4 2 1 9 1 7 18 13 11

SSTBJ and UTI were the most common diagnosis in the remaining group (56.4%); the most commonly prescribed antibacterial for the treatment of SSTBJ infections was flucloxacillin (27.8%), & for UTI was both cefalexin and cefotaxime (61.5%). 28 patients were prescribed antimicrobials for community acquired respiratory tract infections (RESP). The PPS allowed the diagnosis group RESP to be split into sub-groups: Community acquired bronchitis (Bron) Community acquired pneumonia (Pneu) Note: The diagnosis group for one patient in this group was recorded as ProphRes, if the antibacterial was prescribed as prophylaxis then the main indication is a misclassification and should have been recorded as medical prophylaxis (D) and not community acquired infection (A); therefore the patient is excluded from the table below. The number of patients and the antibacterials prescribed for their community acquired bronchitis or pneumonia (CAP) are shown in Table 6. Table 6: Antibacterials prescribed for RTI Indication A No. of Patients Antibacterial/s Pneu Total Amikacin/Clarithromycin/Ethambutol/Rifampicin* 1 1 Amoxicillin 7 7 Amoxicillin/Ciprofloxacin 1 1 Amoxicillin/Clarithromycin 1 1 Amoxicillin/Metronidazole 1 1 Cefalexin/Erythromycin 1 1 Cefotaxime 1 1 2 Cefotaxime/Clarithromycin 1 1 2 Cefotaxime/Clarithromycin/Metronidazole 1 1 Cefotaxime/Metronidazole 1 1 Ceftazidime/Colistin**/Gentamicin** 1 1 Ciprofloxacin 1 1 Clarithromycin 2 2 Co-amoxiclav 2 2 Doxycycline 1 1 Erythromycin 1 1 Gentamicin/Piperacillin 1 1 All-antibacterials 22 5 27 *The regimen for one patient clearly showed the prescribing was for the treatment of a mycobacterial infection (amikacin, clarithromycin, ethambutol & rifampicin). **One patient was prescribed a regimen of parenteral ceftazidime with inhaled colistin & gentamicin suggesting the patient was a cystic fibrosis (CF) patient. 12

For the remaining 25 patients, the BTS guidelines for treatment of a community acquired RTI is amoxicillin or co-amoxiclav +/- clarithromycin: 12 of the 25 patients in this group were prescribed antibacterials that are included in the BTS guidelines (48%) o 7 amoxicillin monotherapy o 1 amoxicillin plus clarithromycin o 2 clarithromycin monotherapy o 2 co-amoxiclav monotherapy In this survey 7 different antimicrobial combinations were prescribed for patients with a diagnosis of community acquired RTI, other than for CF and mycobacterial infection. 13

Hospital Acquired Infections (B) The antibacterials prescribed for hospital acquired infections (B) and the proportion of issues administered parenterally is show in Table 8. 43 patients of the 385 patients surveyed were prescribed antimicrobial/s for hospital acquired infections (11.2%) Of the 133 patients in the survey that were prescribed antibacterials, 43 (33.8%) were indicated for hospital acquired infections (B). 23 different antibacterials were prescribed within this group. Table 8: Antibacterials prescribed for hospital acquired infections (B) Antibacterial ATC code Number of Issues % IV administration Metronidazole J01XD01 14 37.5 Flucloxacillin J01CF05 6 33.3 Cefalexin J01DB01 5 0 Ciprofloxacin J01MA02 5 20 Amoxicillin J01CA04 4 0 Vancomycin J01XA01 4 100 Cefotaxime J01DD01 3 100 Ceftazidime J01DD02 3 100 Co-amoxiclav J01CR02 4 33.3 Erythromycin J01FA01 2 0 Fusidic Acid J01XC01 2 0 Meropenem J01DH02 2 100 Penicillin V J01CE02 2 0 Trimethoprim J01EA01 2 0 Benzylpenicillin J01CE01 1 100 Clarithromycin J01FA09 1 0 Clindamycin J01FF01 1 100 Colisitin J01XB01 1 0** Doxycycline J01AA02 1 0 Gentamicin J01GB03 1 100 Imipenem J01DH51 1 100 Norfloxacin J01MA06 1 0 Piperacillin/Tazobactam J01CR05 3 100 All-antibacterials J01 65 43.1% ** The prescription for colistin was for inhaled use. The antibacterials most commonly prescribed for hospital acquired infections were: Metronidazole (21.5% of all issues for indication B) Flucloxacillin (9.2% of all issues for indication B) Cefalexin (7.7% of all issues for indication B) Ciprofloxacin (7.7% of all issues for indication B) 14

UTI, 12, 18% ENT, 2, 3% GI, 12, 18% GUOB, 3, 5% Not Defined, 2, 3% ENT GI GUOB Not Defined RESP SSTBJ UTI SSTBJ, 21, 33% RESP, 13, 20% Figure 7: Antibacterial prescribed for indication B by diagnosis group Figure 7 shows that 33% of the antibacterials prescribed for hospital acquired infections were for skin soft tissue infections. The PPS included five sub-indications within hospital acquired infection (B): B1 Post-operative infection B2 Other intervention related infections B3 C. difficle associated diarrhoea B4 Other hospital acquired infection B5 Infection present on admission from another hospital The diagnosis groups & sub-indications within the hospital acquired infection group are shown in Table 9. Table 9: Diagnosis group by sub-indication Diagnosis Group B1 B2 B3 B4 ENT 2 GI 2 3 6 1 GUOB 3 Not Defined 2 RESP 2 3 8 SSTBJ 3 3 15 UTI 1 11 All diagnosis 11 9 6 39 B3 there were 6 prescriptions for C. difficle associated diarrhoea B4 other hospital infections were the most common sub-indication recorded accounting for 39 of the 65 prescriptions in this group (60%) 15

The antibacterials prescribed for the sub-indications B1, B2 and B4 are shown in Table 10 (excluding B3). Table 10: Antibacterials prescribed by diagnosis group & sub -indications Antibacterial Name ENT GI GUOB Not Defined RESP SSTBJ UTI Amoxicillin 2 2 Benzylpenicillin 1 Cefalexin 1 1 3 Cefotaxime 1 2 Ceftazidime 1 1 1 Ciprofloxacin 1 4 Clarithromycin 1 Clindamycin 1 Co-amoxiclav 2 Colistin 1 Doxycycline 1 Erythromycin 1 1 Flucloxacillin 6 Fusidic Acid 2 Gentamicin 1 Imipenem 1 Meropenem 1 1 Metronidazole 1 2 1 4 Norfloxacin 1 Penicillin V 2 Piperacillin/Tazobactam 1 Trimethoprim 2 Vancomycin 1 1 1 1 Grand Total 2 6 3 2 13 21 12 Flucloxacillin was the most commonly prescribed antibacterial for SSTBJ infections (27%) Ciprofloxacin was the most commonly prescribed antibacterial for UTIs (33%) The other groups were too small in numbers to draw any conclusions For C. difficle associated diarrhoea (sib-indication B3), metronidazole was prescribed in all cases (100%) 16

Surgical Prophylaxis (Indication C) The antibacterials prescribed for surgical prophylaxis (C) and the proportion of issues administered parenterally is shown in Table 11. 16 of the 385 patients surveyed were prescribed antimicrobial/s for surgical prophylaxis (4.2%) Of the 133 patients in the survey that were prescribed antibacterials, 16 (12%) were indicated for surgical prophylaxis (C). 7 different antibacterials were prescribed within this group. Table 11: Antibacterials prescribed for hospital acquired infections (C) Antibacterial ATC code Number of Issues % IV administration Cefuroxime J01DC02 10 100 Metronidazole J01XD01 3 100 Cefotaxime J01DD01 2 100 Co-amoxiclav J01CR02 1 0 Gentamicin J01GB03 1 100 Trimethoprim J01EA01 1 0 Vancomycin J01XA01 1 100 All-antibacterials J01 19 89.5% Cefuroxime, metronidazole and cefotaxime were the most commonly prescribed antibacterials for surgical prophylaxis (78.9% of all issues) 17of the 19 antibacterials prescribed for surgical prophylaxis were for IV administration only (89.5%) Table 12 shows the antibacterials prescribed by diagnosis group; the most common diagnoses was prophylaxis prior to skin, soft tissue, bone and joint procedures (52.6%) Table 12: Antibacterials prescribed by diagnosis group Indication C Antibacterial Proph CVS Proph ENT Proph GI Proph SBJ Proph UT Cefuroxime 2 Metronidazole 1 9 Cefotaxime 1 Co-amoxiclav 1 Gentamicin 2 1 Trimethoprim 1 Vancomycin 1 All antibacterials 1 1 5 10 2 17

Figure 8 shows that 23 of the 38 antibacterials prescribed (53%) for surgical prophylaxis was for skin, soft tissue bone & joint (Proph SBJ). Proph UT, 2, 11% Proph CVS, 1, 5% Proph ENT, 1, 5% Proph GI, 5, 26% Proph CVS Proph ENT Proph GI Proph SBJ Proph UT Proph SBJ, 10, 53% Figure 8: Antibacterial prescribed for indication C by diagnosis group The PPS included three categories within surgical prophylaxis (C) based on the number of doses of antibacterial prescribed: C1 Single dose C2 One day C3 > 1 day The number of antibacterials prescribed for surgical prophylaxis and the proportion for more than one day duration (C3) is shown in Table 12. 36.8% of antibacterials were prescribed for more than one day in duration. Table 12: Antibacterials prescribed by sub indication C1, C2 & C3 Antibacterial Proportion C3 > I day Name Indication C1 Indication C2 Indication C3 Cefuroxime 7 3 30 Metronidazole 1 2 66.7 Cefotaxime 1 1 50 Co-amoxiclav 1 100 Gentamicin 1 0 Trimethoprim 1 0 Vancomycin 1 0 All antibacterials 1 11 7 36.8% Table 13 shows the diagnosis subgroups and the proportion of antibacterials that were prescribed for more than one day duration (C3); however, the numbers in the some groups are really too small to draw any firm conclusions. 18

Table 13: Diagnosis subgroup by sub indication C1, C2 & C3 Diagnosis subgroup Indication C1 Indication C2 Indication C3 Proportion C3 > I day Proph CVS 1 0 Proph ENT 1 100 Proph GI 2 3 60 Proph SBJ 7 3 30 Proph UT 1 1 0 All diagnosis 1 11 7 36.8% Medical Prophylaxis (Indication D) The antibacterials prescribed for medical prophylaxis (D) and the proportion of issues administered parenterally is shown in Table 14. 4 of the 385 patients surveyed were prescribed an antimicrobial/s for medical prophylaxis (1.0%) Of the 133 patients in the survey that were prescribed antibacterials, 4 (3.0%) were indicated for medical prophylaxis (D). 3 different antibacterials were prescribed within this group. 4 antibacterials (66.7%) were prescribed as medical prophylaxis for GI 3 of the 6 antibacterial were prescribed for IV administration (50%) All ciprofloxacin was prescribed for oral administration Table 14: Antibacterials prescribed for medical prophylaxis Antibacterial ATC code Number of Issues Diagnosis GI Diagnosis Not defined Ciprofloxacin J01MA02 3 1 2 Metronidazole J01XD01 2 2 Cefuroxime J01DC02 1 1 All antibacterials J01 6 4 2 19